AbbVie Inc. (NYSE:ABBV) Shares Sold by Bellecapital International Ltd.

Bellecapital International Ltd. decreased its holdings in AbbVie Inc. (NYSE:ABBVFree Report) by 0.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 62,371 shares of the company’s stock after selling 326 shares during the quarter. AbbVie makes up 2.0% of Bellecapital International Ltd.’s portfolio, making the stock its 16th largest holding. Bellecapital International Ltd.’s holdings in AbbVie were worth $8,403,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. Kalos Management Inc. acquired a new position in shares of AbbVie during the 1st quarter valued at $26,000. Boulder Wealth Advisors LLC bought a new stake in AbbVie in the fourth quarter worth about $31,000. Stone House Investment Management LLC bought a new position in shares of AbbVie during the 1st quarter valued at about $37,000. True Wealth Design LLC acquired a new position in shares of AbbVie in the 4th quarter worth approximately $39,000. Finally, General Partner Inc. acquired a new stake in AbbVie during the first quarter valued at approximately $40,000. 67.86% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Richard A. Gonzalez sold 18,500 shares of AbbVie stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the sale, the chief executive officer now directly owns 625,294 shares of the company’s stock, valued at $93,262,600.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.26% of the stock is currently owned by company insiders.

AbbVie Stock Down 1.0 %

Shares of AbbVie stock opened at $152.09 on Friday. The business’s 50 day simple moving average is $146.09 and its 200 day simple moving average is $147.56. The company has a debt-to-equity ratio of 4.33, a quick ratio of 0.77 and a current ratio of 0.89. The firm has a market cap of $268.45 billion, a PE ratio of 31.29, a P/E/G ratio of 2.74 and a beta of 0.58. AbbVie Inc. has a 52-week low of $130.96 and a 52-week high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last announced its quarterly earnings results on Thursday, July 27th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.12. The firm had revenue of $13.87 billion for the quarter, compared to the consensus estimate of $13.52 billion. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. On average, analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a $1.48 dividend. This represents a $5.92 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Thursday, October 12th. AbbVie’s dividend payout ratio (DPR) is currently 121.81%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABBV. Credit Suisse Group reduced their price objective on AbbVie from $170.00 to $160.00 in a research note on Wednesday, July 12th. Piper Sandler upped their price objective on shares of AbbVie from $163.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, July 28th. William Blair assumed coverage on shares of AbbVie in a research report on Tuesday, July 25th. They issued a “market perform” rating on the stock. HSBC began coverage on shares of AbbVie in a research report on Friday, July 14th. They issued a “buy” rating and a $167.00 price target for the company. Finally, Piper Jaffray Companies lifted their price objective on shares of AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $165.79.

View Our Latest Research Report on AbbVie

AbbVie Profile

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Featured Stories

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.